NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics for central nervous system disorders and life-threatening pulmonary diseases. The company's mission is to address significant unmet medical needs by bringing safe and effective treatments to market for conditions where current therapeutic options are limited or inadequate. NRx Pharmaceuticals is headquartered in Wilmington, Delaware, United States.

The company focuses on neuroplastic therapies, particularly those modulating the N-methyl-D-aspartate (NMDA) receptor. Key product candidates include NRX-100 (preservative-free intravenous ketamine) and NRX-101 (an oral fixed-dose combination of D-cycloserine and lurasidone). These are being developed for conditions such as suicidal depression, bipolar depression, post-traumatic stress disorder (PTSD), and chronic pain. NRX-100 has received Fast Track Designation for suicidal ideation in depression, including bipolar depression, and NRX-101 has been awarded Breakthrough Therapy Designation for suicidal bipolar depression. Through its subsidiary, HOPE Therapeutics, Inc., NRx Pharmaceuticals also provides interventional psychiatry services, including ketamine infusion therapy, transcranial magnetic stimulation (TMS), and digital therapeutics, for patients with treatment-resistant depression and PTSD.

In recent developments, NRx Pharmaceuticals has initiated commercial manufacturing for its preservative-free ketamine product (NRX-100) ahead of an anticipated FDA decision in Q3 2026. The company also announced FDA clearance to proceed with a clinical trial of NRX-101 in combination with robotic-enabled Transcranial Magnetic Stimulation (TMS) for depression and suicidality. NRx Pharmaceuticals recently closed a public offering of common stock, raising approximately $22.3 million in gross proceeds. Dr. Jonathan C. Javitt serves as the Co-Founder, Chairman, and CEO of NRx Pharmaceuticals. The company is actively pursuing FDA approvals for its lead candidates, with NDA filings anticipated for NRX-100 and NRX-101.